Skip to main content

Table 5 Mean changes in HRQoL scores from baseline to study phase completion (week 16) by categories of change in the patient global assessment of disease activity, all dose groups combined

From: Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds

 

Categories of change in patient global assessment of disease activity

 

> +10 (n = 27)

+10 to -10 (n = 64)

-11 to -20 (n = 27)

-21 to -40 (n = 41)

< -40 (n = 23)

F

p-value

PRO Instruments

       

SF-36

       

Physical functioning

-0.9 (19.7)

3.2 (14.2)

10.9 (19.1)

8.3 (17.3)

18.0 (22.4)

4.2

0.0029

Role physical

-0.6 (14.8)

9.4 (19.4)

9.3 (24.1)

6.9 (19.8)

26.1 (30.5)

5.2

0.0006

Bodily pain

-6.9 (11.4)

4.5 (17.1)

11.7 (17.5)

18.1 (13.6)

29.9 (21.9)

19.9

0.0000

General health

-3.9 (11.9)

0.5 (12.5)

4.4 (16.9)

5.3 (12.2)

14.4 (16.5)

6.7

0.0001

Vitality

-3.9 (13.1)

4.4 (17.7)

8.8 (21.2)

7.2 (18.0)

21.7 (25.7)

6.1

0.0001

Social functioning

-6.9 (19.4)

2.1 (21.1)

5.6 (34.1)

10.7 (18.9)

16.8 (35.7)

3.6

0.0081

Role emotional

-7.1 (16.3)

2.9 (27.3)

7.1 (31.2)

4.9 (20.0)

18.8 (27.9)

3.4

0.0101

Mental health

-1.1 (12.4)

3.0 (17.4)

1.4 (22.3)

6.7 (16.1)

11.9 (21.5)

2.1

0.0827

Physical summary

-0.6 (5.9)

1.9 (4.7)

4.5 (6.0)

4.2 (5.7)

9.4 (8.8)

10.4

0.0000

Mental summary

-2.7 (6.9)

1.2 (10.2)

1.4 (12.9)

2.9 (8.7)

7.1 (13.3)

2.9

0.0219

HAQ-DI

0.01 (0.31)

-0.12 (0.37)

-0.32 (0.4)

-0.35 (0.40)

-0.64 (0.58)

10.4

0.0000

FACIT-Fatigue

-1.1 (6.4)

1.94 (7.5)

5.9 (7.4)

3.78 (6.3)

10.72 (9.1)

9.8

0.0000